Immuno-Biological Laboratories Co., Ltd. (TYO:4570)

Japan · Delayed Price · Currency is JPY

1,003.00

-26.00 (-2.53%)

Jul 16, 2026, 10:15 AM JST

101.81% (1Y)

Market Cap	9.58B +96.7%
Revenue (ttm)	1.00B +3.6%
Net Income	329.00M +32.1%
EPS	35.33 +32.1%
Shares Out	9.31M
PE Ratio	29.13
Forward PE	n/a
Dividend	7.50 (0.76%)
Ex-Dividend Date	Mar 30, 2026

Volume	29,400
Open	1,026.00
Previous Close	1,029.00
Day's Range	1,002.00 - 1,031.00
52-Week Range	464.00 - 3,820.00
Beta	-0.02
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 7, 2026

About TYO:4570

Immuno-Biological Laboratories Co., Ltd. engages in the research, development, manufacturing, and supply of various immunological research reagents worldwide. The company offers ELILSA, an assay kit to quantitatively measure targeted substances; and support research services on Alzheimer’s disease, metabolic syndrome, and cancer, as well as customized services for production of customized antibodies and development of ELISA systems. It also provides LipoSEARCH, a customized services for profiling and analyzing of lipoprotein through gel-filtrat... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1982

Employees 54

Stock Exchange Tokyo Stock Exchange

Ticker Symbol 4570

Full Company Profile

Financial Performance

In fiscal year 2026, TYO:4570's revenue was 1.00 billion, an increase of 3.61% compared to the previous year's 969.00 million. Earnings were 329.00 million, an increase of 32.13%.

Financial Statements